Exelixis, Inc. (NASDAQ:EXEL) Expected to Post Earnings of $0.15 Per Share

Equities research analysts expect Exelixis, Inc. (NASDAQ:EXEL) to report $0.15 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Exelixis’ earnings. The highest EPS estimate is $0.17 and the lowest is $0.12. Exelixis posted earnings of $0.37 per share during the same quarter last year, which would indicate a negative year over year growth rate of 59.5%. The firm is scheduled to issue its next earnings results after the market closes on Tuesday, February 25th.

On average, analysts expect that Exelixis will report full year earnings of $0.95 per share for the current year, with EPS estimates ranging from $0.92 to $0.99. For the next financial year, analysts anticipate that the business will report earnings of $0.60 per share, with EPS estimates ranging from $0.33 to $0.82. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Exelixis.

Several equities research analysts recently weighed in on the company. Bank of America reaffirmed a “buy” rating and set a $21.00 price target (down from $22.00) on shares of Exelixis in a report on Monday, January 13th. TheStreet downgraded Exelixis from a “b-” rating to a “c” rating in a report on Friday, November 22nd. SunTrust Banks assumed coverage on Exelixis in a report on Monday, January 13th. They set a “buy” rating and a $31.00 price target for the company. Cowen reaffirmed a “buy” rating and set a $23.00 price target on shares of Exelixis in a report on Sunday, January 12th. Finally, Zacks Investment Research downgraded Exelixis from a “buy” rating to a “hold” rating and set a $20.00 target price for the company. in a report on Friday, January 10th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Exelixis currently has a consensus rating of “Buy” and an average target price of $26.09.

In other news, Director George A. Scangos sold 4,000 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $20.14, for a total value of $80,560.00. Following the completion of the transaction, the director now owns 1,034,031 shares in the company, valued at $20,825,384.34. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michael Morrissey sold 25,000 shares of the firm’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $20.33, for a total value of $508,250.00. The disclosure for this sale can be found here. In the last three months, insiders sold 427,639 shares of company stock valued at $7,914,164. 4.50% of the stock is owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. PNC Financial Services Group Inc. increased its position in shares of Exelixis by 4.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 12,332 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 576 shares in the last quarter. GWM Advisors LLC increased its position in shares of Exelixis by 3.2% in the fourth quarter. GWM Advisors LLC now owns 18,780 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 589 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of Exelixis by 1.1% in the fourth quarter. Municipal Employees Retirement System of Michigan now owns 56,190 shares of the biotechnology company’s stock valued at $990,000 after buying an additional 620 shares in the last quarter. Virtus ETF Advisers LLC increased its position in shares of Exelixis by 1.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 35,810 shares of the biotechnology company’s stock valued at $631,000 after buying an additional 632 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its position in shares of Exelixis by 1.0% in the fourth quarter. Louisiana State Employees Retirement System now owns 73,500 shares of the biotechnology company’s stock valued at $1,295,000 after buying an additional 700 shares in the last quarter. Institutional investors and hedge funds own 77.01% of the company’s stock.

Shares of NASDAQ EXEL traded up $0.52 during mid-day trading on Friday, hitting $20.77. 3,990,132 shares of the company were exchanged, compared to its average volume of 3,595,282. The company has a quick ratio of 6.80, a current ratio of 6.89 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $18.54 and a 200-day simple moving average of $18.28. Exelixis has a 1-year low of $15.02 and a 1-year high of $25.31. The firm has a market cap of $6.15 billion, a price-to-earnings ratio of 10.65, a price-to-earnings-growth ratio of 3.43 and a beta of 1.93.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: 52-Week Highs and Lows

Get a free copy of the Zacks research report on Exelixis (EXEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.